汇宇制药-W
(688553)
| 流通市值：50.08亿 | | | 总市值：68.54亿 |
| 流通股本：3.10亿 | | | 总股本：4.24亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 851,844,303.21 | 532,202,419.92 | 242,604,188.27 | 927,075,092.41 |
| 营业收入 | 851,844,303.21 | 532,202,419.92 | 242,604,188.27 | 927,075,092.41 |
| 二、营业总成本 | 741,467,771.85 | 483,098,243.55 | 215,502,754.93 | 873,711,789.4 |
| 营业成本 | 143,515,070.74 | 94,289,969.57 | 40,734,974.1 | 130,446,547.1 |
| 税金及附加 | 4,728,199.32 | 3,137,120.56 | 1,407,223.88 | 6,727,776.12 |
| 销售费用 | 326,663,876.33 | 204,990,084.52 | 94,803,771.87 | 361,120,674.88 |
| 管理费用 | 55,233,228.17 | 37,324,084.33 | 20,080,199.26 | 76,460,918.51 |
| 研发费用 | 225,022,804.88 | 147,779,271.51 | 65,507,169.1 | 340,758,086.58 |
| 财务费用 | -13,695,407.59 | -4,422,286.94 | -7,030,583.28 | -41,802,213.79 |
| 其中:利息费用 | 9,988,609.6 | 6,996,443.62 | 3,878,190.06 | 6,701,527.04 |
| 其中:利息收入 | -23,234,579.08 | 12,073,510.24 | 10,218,974 | 45,542,835.94 |
| 加:公允价值变动收益 | 115,503,121.76 | - | - | 6,440,469.38 |
| 加:投资收益 | 15,370,176.68 | 8,583,268.7 | 2,350,901.27 | 34,183,058.03 |
| 资产减值损失(新) | -9,604,942.95 | -259,603.59 | 1,817,202.14 | -2,306,756.09 |
| 信用减值损失(新) | -1,595,659.56 | -1,729,744.99 | -1,615,656.36 | -3,896,981.29 |
| 其他收益 | 14,368,447.3 | 9,335,042.25 | 2,419,210.3 | 36,585,364.44 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 244,417,674.59 | 65,033,138.74 | 32,073,090.69 | 124,368,457.48 |
| 加:营业外收入 | 7,232,262.6 | 6,545,362.49 | 5,867,831.32 | 12,061,329.41 |
| 减:营业外支出 | 1,597,389.62 | 245,209.97 | 137,668.59 | 4,275,288.26 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 250,052,547.57 | 71,333,291.26 | 37,803,253.42 | 132,154,498.63 |
| 减:所得税费用 | 29,287,036.19 | 9,128,282.38 | -7,076,081.19 | -7,180,164.59 |
| 六、净利润 | 220,765,511.38 | 62,205,008.88 | 44,879,334.61 | 139,334,663.22 |
| 持续经营净利润 | 220,765,511.38 | 62,205,008.88 | 44,879,334.61 | 139,334,663.22 |
| 归属于母公司股东的净利润 | 227,352,384.74 | 65,213,416.74 | 46,435,905.16 | 139,785,741.88 |
| 少数股东损益 | -6,586,873.36 | -3,008,407.86 | -1,556,570.55 | -451,078.66 |
| (一)基本每股收益 | 0.54 | 0.15 | 0.11 | 0.33 |
| (二)稀释每股收益 | 0.54 | 0.15 | 0.11 | 0.33 |
| 八、其他综合收益 | 1,952,448.71 | 173,085.02 | 69,398.27 | 476,496.07 |
| 归属于母公司股东的其他综合收益 | 1,952,448.71 | 173,085.02 | 69,398.27 | 476,496.07 |
| 九、综合收益总额 | 222,717,960.09 | 62,378,093.9 | 44,948,732.88 | 139,811,159.29 |
| 归属于母公司股东的综合收益总额 | 229,304,833.45 | 65,386,501.76 | 46,505,303.43 | 140,262,237.95 |
| 归属于少数股东的综合收益总额 | -6,586,873.36 | -3,008,407.86 | -1,556,570.55 | -451,078.66 |
| 公告日期 | 2024-10-26 | 2024-08-27 | 2024-04-27 | 2024-04-27 |
| 审计意见(境内) | | | | 标准无保留意见 |